What is retatrutide, and how does it work?

Dr. Linda's take

If you have seen the word "retatrutide" pop up in your feed next to phrases like "next-generation weight loss," I understand the pull to learn more, and I also want to slow things down for a moment. Retatrutide is a real molecule with real published research behind it, and it is also, as of today, not something any clinician can prescribe or any pharmacy can dispense. It is investigational, meaning it is still moving through the clinical trial process that every new medicine has to complete before the FDA will consider it for approval. My goal with this piece is not to sell you on retatrutide or tell you how to get it. It is to walk you through what the science says so far, in plain language, so you understand what it is, how it is designed to work, and where it actually stands in development.

What is retatrutide?

Retatrutide is an investigational medication being developed by Eli Lilly. Unlike a single-target drug, retatrutide is designed as one molecule that activates three separate hormone receptors at once: the receptor for glucose-dependent insulinotropic polypeptide (GIP), the receptor for glucagon-like peptide-1 (GLP-1), and the glucagon receptor. Because it acts on all three, researchers and journalists often describe it as a "triple agonist" or "triple hormone receptor agonist," distinguishing it from single-target GLP-1 medicines like semaglutide and dual-target medicines like tirzepatide.

Retatrutide is not currently approved by the FDA and is considered an investigational medication, and it is not yet available for public use outside of clinical trials. That single fact is the most important thing to understand before reading anything else about it, including this article.

How does retatrutide work?

Each of the three receptors retatrutide activates appears to contribute something different, based on what has been published so far. The GLP-1 receptor is a physiologic regulator of appetite and caloric intake by delaying gastric emptying, and it also plays a role in enhancing first- and second-phase insulin secretion. The GIP receptor targets the brain by stimulating satiety within the hypothalamus, which is thought to contribute to appetite suppression and reduced food intake. The glucagon receptor is different from the other two: glucagon release helps enhance energy expenditure when coupled with GLP-1 and GIP activity, promoting fat breakdown rather than only reducing appetite.

That combination, appetite reduction from two directions plus a metabolic push toward burning stored fat, is the working theory behind why researchers are studying retatrutide as a once-weekly injectable for obesity, and separately for type 2 diabetes and several other conditions. It is a theory actively being tested, not a settled conclusion, which is exactly what the clinical trial process exists to determine.

What have the clinical trials shown so far?

The most substantial published data on retatrutide comes from a phase 2 trial, led by Jastreboff and colleagues and published in the New England Journal of Medicine in 2023. The trial enrolled 338 adults with obesity in a randomized, double-blind, placebo-controlled design, assigning participants to weekly injections of retatrutide at 1 mg, 4 mg, 8 mg, or 12 mg, or to placebo, over 48 weeks.

At the highest dose tested, 12 mg, participants lost an average of 17.5% of their body weight at 24 weeks and 24.2% of their body weight at 48 weeks, compared with roughly 2.1% in the placebo group at 48 weeks. The 8 mg group lost an average of 22.8% of body weight at 48 weeks, and the 4 mg group lost an average of 17.1% at 48 weeks. The most common adverse events reported in the trial were gastrointestinal, including nausea, vomiting, and diarrhea, and these were dose-related and mostly mild to moderate in severity.

Those numbers come from one phase 2 trial in a specific study population, over a specific time frame, and phase 2 results do not always hold at the same magnitude once a larger and longer phase 3 program is complete. Eli Lilly has since moved retatrutide into phase 3 testing under a program it calls TRIUMPH, evaluating retatrutide for chronic weight management and several related conditions, alongside a separate phase 3 program for type 2 diabetes. Ongoing studies will explore the efficacy and safety of retatrutide further before it could be considered for FDA approval, and this article will be updated as that picture develops rather than getting ahead of it.

Is retatrutide FDA-approved or available by prescription?

No. Retatrutide is not FDA-approved for any use, and it is not available by prescription, in a pharmacy, or through a compounding pharmacy. Anyone advertising retatrutide for sale is not offering an FDA-approved medication, and Body Good Studio does not offer, prescribe, or sell retatrutide. If you are looking for a currently FDA-approved option in this medication class, our comparison of retatrutide, Zepbound, and Wegovy lays out which of these three is actually approved today and how the approved options compare to what retatrutide has shown in trials so far.

What are the safety considerations?

Because retatrutide has not completed the full regulatory review process, its long-term safety profile is not yet fully characterized in the way an FDA-approved drug's is, and its labeling has not been finalized. What is known from the phase 2 trial is limited to that trial's population, dosing, and duration, and it will not necessarily match what a larger phase 3 program eventually shows. This is one of the core reasons investigational drugs are studied inside structured clinical trials with safety monitoring, rather than distributed for general use before that process is complete.

What should you ask your clinician?

If you are weighing an FDA-approved option that is available today, Body Good Studio's quiz is built to map your history to a starting point before you talk with a clinician.

Frequently asked questions

Is retatrutide FDA-approved?

No. Retatrutide is not currently approved by the FDA. It is an investigational medication still in clinical development, most recently in phase 3 trials.

Can you get a prescription for retatrutide?

No. Because retatrutide is not FDA-approved, it cannot legally be prescribed or dispensed for general use outside of a clinical trial.

What is retatrutide supposed to do, according to the research so far?

Published phase 2 research shows meaningful average weight loss in a study of adults with obesity over 48 weeks, alongside changes in metabolic markers, but those results come from one trial in a specific population and are not a guarantee of what a final approved product, if any, would show.

How is retatrutide different from semaglutide or tirzepatide?

Semaglutide (Wegovy, Ozempic) targets the GLP-1 receptor alone. Tirzepatide (Zepbound, Mounjaro) targets both the GLP-1 and GIP receptors. Retatrutide is being studied as a triple agonist, adding a third target, the glucagon receptor, on top of GLP-1 and GIP.

When might retatrutide be approved?

There is no confirmed approval date. Retatrutide is currently in phase 3 trials, and Lilly has not announced a specific FDA approval timeline. This article will be updated if that status changes, rather than speculating on a date.

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine, via PubMed (National Library of Medicine). https://pubmed.ncbi.nlm.nih.gov/37366315/ (Accessed 2026-07-12).
2. Alkhezi OS, Alahmed AA, Alfayez OM, Almutairi AR, Almohaini HS, Ahmed W (2024). The "Weight" for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity. Diabetes, Obesity and Metabolism, via PMC (National Library of Medicine). https://pmc.ncbi.nlm.nih.gov/articles/PMC11536522/ (Accessed 2026-07-12).
3. Eli Lilly and Company (2026). What to know about retatrutide. Lilly.com. https://www.lilly.com/news/stories/what-to-know-about-retatrutide (Accessed 2026-07-12).